# US 2026/0069560 A1 · Compositions and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0069560 A1
- Document ID: US20260069560A1
- Status: Published application
- Kind: A1
- Application number: 19/107,637
- Filed: 2023-09-01
- Published: 2026-03-12
- Earliest claimed: 2022-09-02
- Assignees: University of Florida Research Foundation, Inc.; Yale University
- Applicants: University of Florida Research Foundation, Incorporated; Yale University
- Inventors: Christian Jobin; Rachel Newsome; Jason Crawford; Joonseok Oh
- Web page: https://patentgrep.com/patent/US20260069560A1

## CPC

- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- C07C 233/87: of a carbon skeleton containing six-membered aromatic rings
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61K 39/39541: {against normal tissues, cells}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07C 237/52: having the nitrogen atom of at least one of the carboxamide groups further acylated
- C07K 16/2818: {against CD28 or CD152}
- C12N 1/20: Bacteria; Culture media therefor
- C12N 1/205: Bacterial isolates
- A61K 2035/115: {Probiotics}
- A61K 2039/505: {comprising antibodies}
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C12R 2001/01: Bacteria or Actinomycetales {; using bacteria or Actinomycetales}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS

## Abstract

Aspects of the disclosure relate to compositions and methods for modulating the immune response of a subject. The disclosure is based, in part, on compositions comprising one or more compounds that promotes interferon, e.g., interferon gamma (IFNγ), response in the gut microbiome of a subject and/or enhances the anti-tumor effects of certain immune checkpoint inhibitor (ICI) therapies. In some embodiments, the compositions are useful for treating a subject having cancer.

## Claims

### Claim 1

A composition comprising a compound having a structure according to formula (Ia) or a pharmaceutically acceptable salt thereof:

### Claim 2 (depends on 1)

The composition of claim 1, further comprising a compound having a structure according to formula (Ib) or a pharmaceutically acceptable salt thereof:

### Claim 3 (depends on 2)

The composition of claim 2, wherein the compound having a structure according to formula (Ia) and the compound having a structure according to formula (Ib) are provided in a weight ratio in a range of 99:1 to 1:99, for example, 95:5, 90:10, 85:15, 80:20, 75:25, 70:30, 65:35, 60:40, 55:45, 50:50, 45:55, 40:60, 35:65, 30:70, 25:75, 20:80, 15:85, 10:90, or 5:95, or in a range of 99:1 to 50:50, 99:1 to 30:70, 99:1 to 15:85 or 99:1 to 5:95.

### Claim 4 (depends on 1, 2, 3)

The composition of any one of claims 1 to 3, wherein the composition is an aqueous composition.

### Claim 5 (depends on 1, 2, 3, 4)

The composition of any one of claims 1 to 4, further comprising a pharmaceutically acceptable carrier.

### Claim 6 (depends on 1, 2, 3, 4, 5)

Use in the manufacture of a medicament for increasing interferon gamma (IFNγ) secretion in a subject of a composition according to any one of claims 1 to 5.

### Claim 7 (depends on 1, 2, 3, 4, 5)

Use in the manufacture of a medicament for treating cancer of a compound according to any one of claims 1 to 5.

### Claim 8

A method for increasing interferon gamma (IFNγ) secretion in a subject, the method comprising administering to the subject a composition comprising a compound having a structure according to formula (Ia) or a pharmaceutically acceptable salt thereof:

### Claim 9 (depends on 8)

The composition of claim 8, further comprising a compound having a structure according to formula (Ib) or a pharmaceutically acceptable salt thereof:

### Claim 10 (depends on 8, 9)

The method of claim 8 or 9, wherein the subject is a mammal, optionally a human.

### Claim 11 (depends on 8, 9, 10)

The method of any one of claims 8 to 10, wherein the administration comprises oral administration.

### Claim 12 (depends on 8, 9, 10)

The method of any one of claims 8 to 10, wherein the administration comprises parenteral administration.

### Claim 13 (depends on 8, 9, 10, 11, 12)

The method of any one of claims 8 to 12, wherein the composition is an aqueous composition.

### Claim 14 (depends on 8, 9, 10, 11, 12, 13)

The method of any one of claims 8 to 13, wherein the subject has or is suspected of having cancer.

### Claim 15 (depends on 14)

The method of claim 14, wherein the cancer is non-small cell lung carcinoma (NSCLC).

### Claim 16 (depends on 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 8 to 15, further comprising administering an immune checkpoint inhibitor (ICI) to the subject.

### Claim 17 (depends on 16)

The method of claim 16, wherein the ICI comprises an anti-PD-1 antibody.

### Claim 18

A method for treating, ameliorating, or preventing cancer in a subject, the method comprising administering to the subject a composition comprising a compound having a structure according to formula (Ia) or a pharmaceutically acceptable salt thereof:

### Claim 19 (depends on 18)

The composition of claim 18, further comprising a compound having a structure according to formula (Ib) or a pharmaceutically acceptable salt thereof:

### Claim 20 (depends on 18, 19)

The method of claim 18 or 19, wherein the subject is a mammal, optionally a human.

### Claim 21 (depends on 18, 19, 20)

The method of any one of claims 18 to 20, wherein the administration comprises oral administration.

### Claim 22 (depends on 18, 19, 20)

The method of any one of claims 18 to 20, wherein the administration comprises parenteral administration.

### Claim 23 (depends on 18, 19, 20, 21, 22)

The method of any one of claims 18 to 22, wherein the composition is an aqueous composition.

### Claim 24 (depends on 18, 19, 20, 21, 22, 23)

The method of any one of claims 18 to 23, wherein the cancer is non-small cell lung carcinoma (NSCLC).

### Claim 25 (depends on 18, 19, 20, 21, 22, 23, 24)

The method of any one of claims 18 to 24, further comprising administering an immune checkpoint inhibitor (ICI) to the subject.

### Claim 26 (depends on 25)

The method of claim 25, wherein the ICI comprises an anti-PD-1 antibody.

### Claim 27 (depends on 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 18 to 26, wherein after the administration of the composition, interferon gamma (IFNγ) secretion is increased in the subject relative to IFNγ secretion before the administration.

### Claim 28

A composition comprising a cell-free isolate obtained from Bacteroides ovatus, wherein the cell free isolate comprises:
(i) a first agent having a mass-to-charge ratio (m/z) of 417.2948;
(ii) a second agent compound having a m/z of 296.25818;
(iii) a third agent having a m/z of 317.20602;
(iv) a fourth agent having a m/z of 298.2737; and
(v) a fifth agent having a m/z of and 430.33078.

### Claim 29 (depends on 28)

The composition of claim 28, wherein each of the first, second, third, fourth, and fifth agents is independently selected from a peptide, protein, or small molecule.

### Claim 30 (depends on 28, 29)

A method for increasing interferon gamma (IFNγ) secretion in a subject, the method comprising administering to the subject the composition of claim 28 or 29.

### Claim 31 (depends on 28, 29, 30)

A method for treating, ameliorating, or preventing cancer in a subject, the method comprising administering to the subject the composition of any one of claims 28 to 30.

### Claim 32 (depends on 30, 31)

The method of claim 30 or 31, wherein the subject is a mammal, optionally a human.

### Claim 33 (depends on 30, 31, 32)

The method of any one of claims 30 to 32, wherein the administration comprises oral administration.

### Claim 34 (depends on 30, 31, 32)

The method of any one of claims 30 to 32, wherein the administration comprises parenteral administration.

### Claim 35 (depends on 30, 31, 32, 33, 34)

The method of any one of claims 30 to 34, wherein the composition is an aqueous composition.

### Claim 36 (depends on 31, 32, 33, 34, 35)

The method of any one of claims 31 to 35, wherein the subject has or is suspected of having cancer.

### Claim 37 (depends on 36)

The method of claim 36, wherein the cancer is non-small cell lung carcinoma (NSCLC).

### Claim 38 (depends on 30, 31, 32, 33, 34, 35, 36, 37)

The method of any one of claims 30 to 37, further comprising administering an immune checkpoint inhibitor (ICI) to the subject.

### Claim 39 (depends on 38)

The method of claim 38, wherein the ICI comprises an anti-PD-1 antibody.
